BRPI0516476A - vlp antigen conjugates and their use as vaccines - Google Patents
vlp antigen conjugates and their use as vaccinesInfo
- Publication number
- BRPI0516476A BRPI0516476A BRPI0516476-1A BRPI0516476A BRPI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A
- Authority
- BR
- Brazil
- Prior art keywords
- vlp
- antigen
- vaccines
- compositions
- secondary structure
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
CONJUGADOS DE ANTìGENO DE VLP E SEU USO COMO VACINAS. A presente invenção é relacionada com os campos de biologia, virologia, imunologia e medicina molecular. A invenção fornece uma composição que compreende uma partícula semelhante a vírus (VLP) de um RNA-bacteriáfago e pelo menos um antígeno, em que a VLP é recombinantemente produzida em um hospedeiro, e em que a quantidade de RNA hospedeiro com estrutura secundária compreendida pela VLP é no máximo 20 % da quantidade de RNA hospedeiro com estrutura secundária originalmente compreendida pela VLP; e em que a VLP e o pelo menos um antígeno são ligados um com o outro. A invenção também fornece métodos para a produção das composições da invenção. As composições da invenção são úteis na produção de vacinas para o tratamento de doenças, distúrbios e condições. Além disso, as composições da invenção são particularmente úteis para eficientemente induzir respostas de anticorpo fortes contra o antígeno dentro do contexto indicado enquanto diminui ou elimina as respostas da célula T indesejáveis.VLP ANTIGEN ASSEMBLIES AND THEIR USE AS VACCINES. The present invention relates to the fields of biology, virology, immunology and molecular medicine. The invention provides a composition comprising a virus-like particle (VLP) of a bacteriophage RNA and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of secondary structure host RNA comprised by VLP is at most 20% of the amount of secondary structure host RNA originally comprised by VLP; and wherein the VLP and at least one antigen are linked with each other. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in producing vaccines for the treatment of diseases, disorders and conditions. In addition, the compositions of the invention are particularly useful for efficiently inducing strong antigen antibody responses within the indicated context while decreasing or eliminating undesirable T cell responses.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61563704P | 2004-10-05 | 2004-10-05 | |
EP05105228 | 2005-06-14 | ||
PCT/EP2005/055009 WO2006037787A2 (en) | 2004-10-05 | 2005-10-05 | Vlp-antigen conjugates and their uses as vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516476A true BRPI0516476A (en) | 2008-09-02 |
Family
ID=39445825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516476-1A BRPI0516476A (en) | 2004-10-05 | 2005-10-05 | vlp antigen conjugates and their use as vaccines |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2008515851A (en) |
BR (1) | BRPI0516476A (en) |
IL (1) | IL181228A0 (en) |
MX (1) | MX2007003954A (en) |
NZ (1) | NZ554388A (en) |
RU (1) | RU2417793C2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012125190A (en) * | 2010-12-15 | 2012-07-05 | Kakei Gakuen | Linker peptide for making association unit |
JPWO2022230485A1 (en) * | 2021-04-26 | 2022-11-03 | ||
WO2024005668A1 (en) * | 2022-06-28 | 2024-01-04 | Андрей Николаевич ВОЛОГОДСКИЙ | Method for producing bacteriophage virus-like particles |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU764138B2 (en) * | 1999-02-05 | 2003-08-14 | Merck Sharp & Dohme Corp. | Human papilloma virus vaccine formulations |
CA2492826C (en) * | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
-
2005
- 2005-10-05 BR BRPI0516476-1A patent/BRPI0516476A/en not_active IP Right Cessation
- 2005-10-05 JP JP2007535158A patent/JP2008515851A/en active Pending
- 2005-10-05 MX MX2007003954A patent/MX2007003954A/en not_active Application Discontinuation
- 2005-10-05 RU RU2007116717/10A patent/RU2417793C2/en not_active IP Right Cessation
- 2005-10-05 NZ NZ554388A patent/NZ554388A/en not_active IP Right Cessation
-
2007
- 2007-02-08 IL IL181228A patent/IL181228A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2007003954A (en) | 2007-06-14 |
RU2007116717A (en) | 2008-11-20 |
NZ554388A (en) | 2010-01-29 |
IL181228A0 (en) | 2008-04-13 |
JP2008515851A (en) | 2008-05-15 |
RU2417793C2 (en) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006037787A3 (en) | Vlp-antigen conjugates and their uses as vaccines | |
BRPI0519026A2 (en) | il-15 antigen arrangements and uses thereof | |
Rappuoli et al. | Vaccines, new opportunities for a new society | |
BRPI0507002A (en) | vehicles ghrelin conjugates | |
BRPI0518761A2 (en) | drug fusion, drug conjugate, Recombinant Nucleic Acid, Nucleic Acid Construction, Host Cell, Method for Producing a Drug Fusion, Pharmaceutical Composition, Drug, Method of Treatment and / or Prevention of a Condition in a Patient, Delay Method or prevention of disease progression, and a method for decreasing food absorption by a patient | |
AR066198A1 (en) | ANTI IGE APOPTOTIC ANTIBODIES | |
BRPI0516775A (en) | gastric inhibitor antigen (gip) polypeptide assays and their uses | |
BR0310088A (en) | Drug pre-targeting by bispecific antibodies and haptenic constructs comprising a peptide vehicle and the active agent (s) | |
JP2017079745A (en) | COMPLEXES OF IL-15 AND IL-15Rα AND USE THEREOF | |
BR112012001984B8 (en) | human antibodies with high affinity for human angiopoietin-2, their use and pharmaceutical composition | |
BRPI0617664B8 (en) | use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction | |
BRPI0518101A (en) | methods of production and synthesis of nanoparticulate compositions, compositions obtained and their use | |
BRPI0518762A2 (en) | drug fusion, drug conjugate, recombinant or isolated nucleic acid, nucleic acid construct, host cell, method for producing drug fusion, pharmaceutical composition, method for treating an individual having an inflammatory disease, use of a drug conjugate or drug fusion, and, drug composition | |
BR112013002940A2 (en) | new vaccine adjuvants based on targeting adjuvants for antibodies directly to antigen presenting cells | |
BRPI0415622B8 (en) | use of an immortalized duck somite or retinal cell line, as well as methods for preparing an immortalized duck somite or duck retina cell line, and for virus production | |
NO20083062L (en) | Human monoclonal antibodies to fucosyl GM1 and methods for using anti-fucosyl GM1 | |
BRPI0612656A8 (en) | immunogenic composition, vaccine, vaccine kit for concomitant or sequential administration, process for producing the vaccine, method of immunizing a human host against disease caused by neisseria meningitidis infection, and use of the immunogenic composition | |
BRPI0416205A (en) | use of antibiotics as vaccine adjuvants | |
BR0209689A (en) | Use of hmg fragment as anti-inflammatory agent | |
BR112021023048A2 (en) | cd19 binding molecules and uses thereof | |
BR112012009289A8 (en) | METHOD FOR PURIFIING AN ANTI-IL-13 ANTIBODY FROM A SAMPLE MIXTURE COMPRISING AN ANTI-IL-13 ANTIBODY AND AT LEAST ONE HOST CELL PROTEIN (HCP) | |
BR0207283A (en) | Reduced immunogenicity modified anti-egfr antibodies | |
WO2013177214A3 (en) | Epitope focusing by variable effective antigen surface concentration | |
AR083546A1 (en) | TREATMENT OF GASTROINTESTINAL INFLAMMATION, SORIASIS AND ASTHMA | |
ECSP088636A (en) | ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME, AND METHODS OF USE IN CANCER THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013. |